S. Landis, T. Murray, S. Bolden, and P. Wingo, Cancer statistics, 1999, Cancer statistics, pp.8-31, 1999.
DOI : 10.3322/canjclin.49.1.8

G. Mundy, Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.2, issue.8, pp.584-93, 2002.
DOI : 10.1038/nrc867

N. Clarke, J. Mcclure, and N. George, Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer, British Journal of Urology, vol.3, issue.Suppl. 1, pp.74-80, 1991.
DOI : 10.1111/j.1464-410X.1991.tb15260.x

P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R. Coleman et al., Markers of bone turnover for the management of patients with bone metastases from prostate cancer, British Journal of Cancer, vol.82, issue.4, pp.858-64, 2000.
DOI : 10.1054/bjoc.1999.1012

K. Shimizu, N. Takaha, N. Nonomura, and A. Okuyama, Prostate cancer mediates osteoclastogenesis through two different pathways, Cancer Lett, vol.223, pp.121-129, 2005.

J. Zhang, J. Dai, Y. Qi, D. Lin, P. Smith et al., Osteoprotegerin inhibits prostate cancer???induced osteoclastogenesis and prevents prostate tumor growth in the bone, Journal of Clinical Investigation, vol.107, issue.10, pp.1235-1279, 2001.
DOI : 10.1172/JCI11685

J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall et al., Soluble receptor activator of nuclear factor ?B Fc diminishes prostate cancer progression in bone, Cancer Res, vol.63, pp.7883-90, 2003.

E. Corey, L. Brown, J. Kiefer, J. Quinn, T. Pitts et al., Osteoprotegerin in Prostate Cancer Bone Metastasis, Cancer Research, vol.65, issue.5, pp.1710-1718, 2005.
DOI : 10.1158/0008-5472.CAN-04-2033

P. Whang, E. Schwarz, S. Gamradt, W. Dougall, and J. Lieberman, The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone, Journal of Orthopaedic Research, vol.63, issue.6, pp.1475-83, 2005.
DOI : 10.1016/j.orthres.2005.05.004.1100230634

S. Théoleyre, Y. Wittrant, S. Tat, Y. Fortun, F. Rédini et al., The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-75, 2004.
DOI : 10.1016/j.cytogfr.2004.06.004

L. Hofbauer, A. Neubauer, and A. Heufelder, Receptor activator of nuclear factor-??B ligand and osteoprotegerin, Cancer, vol.3, issue.Suppl 1, pp.460-70, 2001.
DOI : 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D

Y. Kong, H. Yoshida, I. Sarosi, H. Tan, E. Timms et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, vol.397, pp.315-338, 1999.

T. Burgess, Y. Qian, S. Kaufman, B. Ring, G. Van et al., The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts, The Journal of Cell Biology, vol.108, issue.3, pp.327-365, 1999.
DOI : 10.1016/0006-291X(89)91143-1

S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998.

S. Morony, G. Shimamoto, M. Bass, and W. Boyle, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

R. Rank, OPG: new therapeutic targets in bone tumors and associated osteolysis

J. Brown, E. Corey, Z. Lee, L. True, T. Yun et al., Osteoprotegerin and rank ligand expression in prostate cancer, Urology, vol.57, issue.4, pp.611-617, 2001.
DOI : 10.1016/S0090-4295(00)01122-5

J. Brown, R. Vessella, P. Kostenuik, C. Dunstan, P. Lange et al., Serum osteoprotegerin levels are increased in patients with advanced prostate cancer, Clin Cancer Res, vol.7, pp.2977-83, 2001.

I. Holen, P. Croucher, F. Hamdy, and C. Eaton, Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Res, vol.62, pp.1619-1642, 2002.

K. Higashio, RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem Biophys Res Commun, vol.253, pp.395-400, 1998.

Y. Wittrant, F. Lamoureux, K. Mori, A. Riet, A. Kamijo et al., RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, International Journal of Oncology
DOI : 10.3892/ijo.28.1.261

URL : https://hal.archives-ouvertes.fr/inserm-00667510

J. Chirgwin and T. Guise, Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases, Critical Reviews?? in Eukaryotic Gene Expression, vol.10, issue.2, pp.159-78, 2000.
DOI : 10.1615/CritRevEukarGeneExpr.v10.i2.50

J. Chirgwin, K. Mohammad, and T. Guise, Tumor-bone cellular interactions in skeletal metastases, J Musculoskelet Neuronal Interact, vol.4, pp.308-326, 2004.

T. Guise and J. Chirgwin, Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases, Clinical Orthopaedics and Related Research, vol.415, pp.32-40, 2003.
DOI : 10.1097/01.blo.0000093055.96273.69

M. Hansen, S. Nielsen, and K. Berg, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, Journal of Immunological Methods, vol.119, issue.2, pp.203-213, 1989.
DOI : 10.1016/0022-1759(89)90397-9

C. Chipoy, M. Berreur, S. Couillaud, G. Pradal, F. Vallette et al., Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKC?? and STAT3, Journal of Bone and Mineral Research, vol.100, issue.Suppl, pp.1850-61, 2004.
DOI : 10.1359/JBMR.040817

J. Fisher, J. Schmitt, M. Howard, P. Mackie, P. Choong et al., An in vivo model of prostate carcinoma growth and invasion in bone, Cell and Tissue Research, vol.307, issue.3, pp.337-382, 2002.
DOI : 10.1007/s00441-001-0503-x

R. Khokha, T. Wada, and J. Penninger, Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.440, pp.692-698, 2006.

Z. Lee and H. Kim, Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts, Biochemical and Biophysical Research Communications, vol.305, issue.2, pp.211-215, 2003.
DOI : 10.1016/S0006-291X(03)00695-8

T. Guise, The vicious cycle of bone metastases, J Musculoskelet Neuronal Interact, vol.2, pp.570-572, 2002.

C. Kim, L. You, C. Yellowley, and C. Jacobs, Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling, Bone, vol.39, issue.5, 2006.
DOI : 10.1016/j.bone.2006.05.017

K. Tat, S. Padrines, M. Theoleyre, S. Heymann, D. Fortun et al., IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology, Cytokine Growth Factor Rev, vol.15, pp.49-60, 2004.

N. Franchimont, S. Wertz, and M. Malaise, Interleukin-6: An osteotropic factor influencing bone formation?, Bone, vol.37, issue.5, pp.601-607, 2005.
DOI : 10.1016/j.bone.2005.06.002

S. Mori, K. Murakami-mori, and B. Bonavida, Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines, Anticancer Res, vol.18, pp.4403-4411, 1998.

T. Chung, J. Yu, M. Spiotto, M. Bartkowski, and J. Simons, Characterization of the role of IL-6 in the progression of prostate cancer, The Prostate, vol.55, issue.3, pp.199-207, 1999.
DOI : 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H

P. Smith, A. Hobisch, D. Lin, Z. Culig, and E. Keller, Interleukin-6 and prostate cancer progression, Cytokine & Growth Factor Reviews, vol.12, issue.1, pp.33-40, 2001.
DOI : 10.1016/S1359-6101(00)00021-6

S. Paget, The distrubution of secondary growths in cancer of the breast, Lancet, vol.1, pp.571-573, 1889.

P. Bhatia, M. Sanders, and M. Hansen, Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma, Clin Cancer Res, vol.11, pp.162-167, 2005.